In undertaking this survey, researchers aimed to assess the limitations of ctDNA testing in the clinic, as well as areas in which it is considered clinically meaningful.

Ultrasensitive ctDNA testing distinguishes patients with very different risks for recurrence — but it remains to be seen whether acting on the results can improve their outcomes.

Dr. Hua-Jay Cherng, a hematologist oncologist at NewYork-Presbyterian/Columbia University Medical Center, discussed how ctDNA ...

Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes This retrospective analysis included patients with ...

Scientists have found that a blood-based test may help guide treatment decisions for a selected group of women aged 70 and ...

India, March 23 -- Advances in cancer research are improving how doctors diagnose and monitor diseases. One emerging tool is ...

With March being colon cancer awareness month, it’s a good time to look at some startling numbers on the disease here in the ...

As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...

Molecular recurrence signals preceded symptoms or imaging in all recurrences observed, indicating ctDNA may enable earlier ...

Serial circulating tumor DNA (ctDNA) testing showed limited clinical benefit in colorectal cancer (CRC) surveillance when frequent imaging is used. The study's retrospective design and small sample ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their ...